Because ovarian cancer initiated a stealthy assault before I discovered it, it seems the clear aggressor, and I the injured party. Yet as my physicians use their weapons to counterattack, collateral damages mount. Fatigue envelops me.
Sometimes the arsenal deployed against recurrent cancer feels like overkill. Often I wonder what will happen if and when the drug of the clinical trial in which I am enrolled fails to keep my cancer at bay. Will I have the resources to undergo surgery or chemotherapy again?
Read Full Article Here >>